Publications

Detailed Information

Fate of Surgical Patients with Small Nonfunctioning Pancreatic Neuroendocrine Tumors: An International Study Using Multi-Institutional Registries

Cited 2 time in Web of Science Cited 4 time in Scopus
Authors

Han, In Woong; Park, Jangho; Park, Eun Young; Yoon, So Jeong; Jin, Gang; Hwang, Dae Wook; Jiang, Kuirong; Kwon, Wooil; Xu, Xuefeng; Heo, Jin Seok; Fu, De-Liang; Lee, Woo Jung; Bai, Xueli; Yoon, Yoo-Seok; Yang, Yin-Mo; Ahn, Keun Soo; Yuan, Chunhui; Lee, Hyeon Kook; Sun, Bei; Park, Eun Kyu; Lee, Seung Eun; Kang, Sunghwa; Lou, Wenhui; Park, Sang-Jae

Issue Date
2022-02
Publisher
Multidisciplinary Digital Publishing Institute (MDPI)
Citation
Cancers, Vol.14 No.4, p. 1038
Abstract
Simple Summary No consensus has been reached regarding whether nonmetastatic nonfunctioning neuroendocrine tumors of the pancreas (NF-pNETs) <= 2 cm should be resected or observed. In this retrospective international multicenter study, 483 patients who underwent resection for NF-pNETs <= 2 cm in 18 institutions from 2000 to 2017 were enrolled and their medical records were reviewed. Tumor size > 1.5 cm, Ki-67 index >= 3%, and nodal metastasis were independent adverse prognostic factors for survival after multivariable analysis. NF-pNET patients with tumors <= 1.5 cm can be observed if the preoperative Ki-67 index is under 3%, and if nodal metastasis is not suspected in preoperative radiologic studies. These findings support the clinical use to make decisions about small NF-pNETs. Several treatment guidelines for sporadic, nonmetastatic nonfunctioning neuroendocrine tumors of the pancreas (NF-pNETs) have recommended resection, however, tumors <= 2 cm do not necessarily need surgery. This study aims to establish a surgical treatment plan for NF-pNETs <= 2 cm. From 2000 to 2017, 483 patients who underwent resection for NF-pNETs <= 2 cm in 18 institutions from Korea and China were enrolled and their medical records were reviewed. The median age was 56 (range 16-80) years. The 10-year overall survival rate (10Y-OS) and recurrence-free survival rate (10Y-RFS) were 89.8 and 93.1%, respectively. In multivariable analysis, tumor size (>1.5 cm; HR 4.28, 95% CI 1.80-10.18, p = 0.001) and nodal metastasis (HR 3.32, 95% CI 1.29-8.50, p = 0.013) were independent adverse prognostic factors for OS. Perineural invasion (HR 4.36, 95% CI 1.48-12.87, p = 0.008) and high Ki-67 index (>= 3%; HR 9.06, 95% CI 3.01-27.30, p < 0.001) were independent prognostic factors for poor RFS. NF-pNETs <= 2 cm showed unfavorable prognosis after resection when the tumor was larger than 1.5 cm, Ki-67 index >= 3%, or nodal metastasis was present. NF-pNET patients with tumors <= 1.5 cm can be observed if the preoperative Ki-67 index is under 3%, and if nodal metastasis is not suspected in preoperative radiologic studies. These findings support the clinical use to make decisions about small NF-pNETs.
ISSN
2072-6694
URI
https://hdl.handle.net/10371/178009
DOI
https://doi.org/10.3390/cancers14041038
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share